Patents by Inventor George Tidmarsh

George Tidmarsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180311306
    Abstract: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
    Type: Application
    Filed: June 22, 2018
    Publication date: November 1, 2018
    Inventors: George Tidmarsh, Lakhmir Chawla
  • Publication number: 20180099023
    Abstract: Provided herein are compositions and methods related to the use of hepcidin and/or hepcidin analogues for the treatment and/or prevention of iron overload in a subject (e.g., a human subject) and/or for reducing serum iron levels in a subject without inducing serum iron rebound.
    Type: Application
    Filed: September 6, 2017
    Publication date: April 12, 2018
    Inventors: George Tidmarsh, Lakhmir Chawla
  • Publication number: 20170246256
    Abstract: The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.
    Type: Application
    Filed: January 6, 2017
    Publication date: August 31, 2017
    Inventors: George Tidmarsh, Lakhmir Chawla
  • Publication number: 20170224761
    Abstract: The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
    Type: Application
    Filed: January 6, 2017
    Publication date: August 10, 2017
    Inventors: George Tidmarsh, Lakhmir Chawla
  • Publication number: 20170218005
    Abstract: Various aspects of the invention relate to compositions comprising C-2a gentamicin. A composition may be substantially free from one or more of C-1 gentamicin, C-1a gentamicin, C-2 gentamicin, C-2b gentamicin, gentamicin A, gentamicin B, and gentamicin X. In some aspects, the invention relates to a method for treating a condition in a subject, comprising administering a composition comprising C-2a gentamicin to the subject. The condition may be, for example, a bacterial infection, genetic disease or disorder, or cancer.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 3, 2017
    Inventors: George Tidmarsh, James Rolke, Lakhmir Chawla
  • Publication number: 20170157161
    Abstract: Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.
    Type: Application
    Filed: December 7, 2015
    Publication date: June 8, 2017
    Inventor: George Tidmarsh
  • Publication number: 20170014446
    Abstract: The invention provides methods for the treatment of diseases and conditions relating to galectin 3 using a galectin-3 inhibitor, such as a modified pectin (e.g., GCS-100). Also described are methods for conjoint therapy, and methods for assessing and/or monitoring the effects of a galectin-3 inhibitor, e.g., to adapt the dosing regimen of the inhibitor during therapy.
    Type: Application
    Filed: March 10, 2015
    Publication date: January 19, 2017
    Applicant: LA JOLLA PHARMACEUTICAL COMPANY
    Inventors: James Rolke, George Tidmarsh
  • Publication number: 20170014471
    Abstract: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Inventor: George Tidmarsh
  • Patent number: 9457059
    Abstract: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: October 4, 2016
    Assignee: La Jolla Pharmaceutical Company
    Inventor: George Tidmarsh
  • Publication number: 20160074465
    Abstract: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
    Type: Application
    Filed: July 8, 2015
    Publication date: March 17, 2016
    Inventor: George Tidmarsh
  • Patent number: 9205098
    Abstract: Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: December 8, 2015
    Assignee: Threshold Pharmaceuticals
    Inventor: George Tidmarsh
  • Publication number: 20140329747
    Abstract: The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 6, 2014
    Applicant: La Jolla Pharmaceutical Company
    Inventor: George Tidmarsh
  • Publication number: 20130011476
    Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Jerry Xu, George Tidmarsh
  • Publication number: 20130011475
    Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Jerry Xu, George Tidmarsh
  • Patent number: 8318683
    Abstract: Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: November 27, 2012
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventor: George Tidmarsh
  • Publication number: 20120156292
    Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 21, 2012
    Inventors: Jerry Xu, George Tidmarsh
  • Publication number: 20120156291
    Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 21, 2012
    Inventors: Jerry Xu, George Tidmarsh
  • Publication number: 20110311637
    Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 22, 2011
    Inventors: George Tidmarsh, Barry L. Golombik, Puneet Sharma
  • Publication number: 20110313009
    Abstract: The present invention generally relates to unit dosage forms of naproxen and H2-receptor antagonists, comprising an immediate-release formulation of naproxen; an immediate-release formulation of an H2-receptor antagonist, and a delayed-burst release formulation of an H2-receptor antagonist.
    Type: Application
    Filed: July 17, 2009
    Publication date: December 22, 2011
    Inventors: George Tidmarsh, Leah Appel
  • Publication number: 20110311636
    Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 22, 2011
    Inventors: George Tidmarsh, Barry L. Golombik, Puneet Sharma